Skip to content
Screener

Myriad Genetics MYGN RoW — Revenue

Similar metrics at other companies

Insperity logo
NSPOther Revenues — Revenue
$19M-9.5%
Nucor logo
NUERaw Materials — Revenue
$3.09B+13.2%
Nucor logo
NUERaw Materials — Revenue
$674M+30.1%
Unity Software logo
UGrow Solutions — Revenue
$388.85M+35.4%
News Corporation logo
NWSDow Jones — Revenue
$644M+6.6%
SPX Technologies logo
SPXCRevenues — Revenue
$394M+22.0%

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$310.86M-46.0%
Enterprise value$396.36M-38.7%
P/S0.4×-0.3×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Myriad Genetics’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 6:05 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000899923-26-000038
(in millions)Three months ended March 31, 2026 / U.S.Three months ended March 31, 2026 / Ro WThree months ended March 31, 2026 / TotalThree months ended March 31, 2025 / U.S.Three months ended March 31, 2025 / Ro WThree months ended March 31, 2025 / Total
Cancer Care Continuum$106.8$13.4$120.2$101.4$14.2$115.6
Prenatal Health41.941.949.20.149.3
Mental Health38.338.331.031.0
Total revenue$187.0$13.4$200.4$181.6$14.3$195.9

Item 1. Financial Statements.

FAQ

What is Myriad Genetics's row — revenue?
Myriad Genetics (MYGN) reported row — revenue of $13.4M in Q1 2026.
How has Myriad Genetics's row — revenue changed year-over-year?
Myriad Genetics's row — revenue decreased by 6.3% year-over-year, from $14.3M to $13.4M.
What is the long-term trend for Myriad Genetics's row — revenue?
Over 4 years (2021 to 2025), Myriad Genetics's row — revenue has grown at a -10.2% compound annual growth rate (CAGR), from $86.9M to $56.5M.
What does row — revenue mean?
This metric represents the total revenue generated from the company's operations outside of its primary domestic market. It serves as a key indicator of the firm's international market penetration and the scalability of its diagnostic testing services in global territories. Tracking this figure helps investors assess geographic diversification and the impact of international regulatory or competitive environments on overall top-line performance.

Ask your AI about Myriad Genetics's row — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude